Research Analysts Set Expectations for XOMA Q1 Earnings

XOMA Co. (NASDAQ:XOMA) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for XOMA in a note issued to investors on Wednesday, March 19th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings per share of ($0.20) for the quarter. HC Wainwright currently has a “Buy” rating and a $104.00 price target on the stock. The consensus estimate for XOMA’s current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for XOMA’s Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at $0.23 EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at $0.12 EPS.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). The firm had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%.

Separately, StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a research note on Friday.

XOMA Stock Down 0.9 %

NASDAQ:XOMA opened at $20.88 on Friday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The stock has a 50-day simple moving average of $24.37 and a 200 day simple moving average of $27.13. The company has a market cap of $250.12 million, a PE ratio of -6.00 and a beta of 1.00. XOMA has a 52-week low of $19.92 and a 52-week high of $35.00.

Institutional Trading of XOMA

Several institutional investors have recently added to or reduced their stakes in the company. Nuveen Asset Management LLC boosted its stake in XOMA by 3.8% in the 4th quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 527 shares during the period. BNP Paribas Financial Markets lifted its position in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares during the period. New York State Common Retirement Fund lifted its position in shares of XOMA by 51.2% during the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 800 shares during the period. Eversept Partners LP lifted its position in shares of XOMA by 1.2% during the 4th quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company’s stock valued at $2,508,000 after acquiring an additional 1,128 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after acquiring an additional 1,138 shares during the period. 95.92% of the stock is currently owned by institutional investors.

Insider Transactions at XOMA

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.20% of the stock is currently owned by corporate insiders.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.